Charles King, MD
Rheumatology · Tupelo, MSNPI 1538137989
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,100 of the $13,288 with a category attached, or 68.5%. Pfizer accounts for 70.6% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2021 at $5,440 and has fallen 95.4% since, to $248 in 2025.
Across 235 payments — averaging $56.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$9K
- AbbVie$2K
- Amgen$571
- GSK$259
- Novartis$245
- E.r. Squibb & Sons, L.L.C.$204
- plus $707 from 13 others
Across 94 payments — averaging $4167.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$266K
- AbbVie$68K
- Eli Lilly$28K
- GSK$14K
- Janssen Research & Development, LLC$7K
- Amgen$6K
- plus $2K from 1 others
What the payments were for
- Speaking & faculty fees$9,10068%
- Food & beverage$4,17031%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 20 | $9,380 |
| AbbVie | 99 | $1,921 |
| Amgen | 52 | $571 |
| GSK | 12 | $259 |
| Novartis | 13 | $245 |
| E.r. Squibb & Sons, L.L.C. | 14 | $204 |
| Abbott | 2 | $158 |
| AstraZeneca | 1 | $100 |
| Lilly USA, LLC | 2 | $87 |
| Aurinia Pharma U.S., Inc. | 3 | $66 |
| Genentech USA, Inc. | 4 | $60 |
| Sandoz | 3 | $60 |
| Sobi, Inc | 2 | $36 |
| Johnson & Johnson(2 entities) | 2 | $32 |
| UCB, Inc. | 2 | $30 |
| Octapharma USA, Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $19 |
| Organon | 1 | $17 |
| Fresenius Kabi USA, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,288 in reported general payments places this provider in the 65th percentile of 44 rheumatology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 744 | $5,069,969 |
| Humira(Cf) PenAdalimumab | 311 | $2,298,128 |
| Enbrel SureclickEtanercept | 275 | $2,131,287 |
| HumiraAdalimumab | 213 | $1,446,992 |
| RinvoqUpadacitinib | 176 | $1,099,293 |
| Orencia ClickjectAbatacept | 156 | $867,011 |
| ForteoTeriparatide | 172 | $666,831 |
| EnbrelEtanercept | 68 | $569,274 |
| Skyrizi PenRisankizumab-Rzaa | 24 | $462,703 |
| Xeljanz XrTofacitinib Citrate | 75 | $451,463 |
| OrenciaAbatacept | 57 | $365,682 |
| Enbrel MiniEtanercept | 41 | $313,126 |
| Taltz AutoinjectorIxekizumab | 45 | $304,766 |
| Actemra ActpenTocilizumab | 84 | $287,778 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 39 | $278,793 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira, Rinvoq, Humira(Cf) | $1,921 | $2,649,135402 claims |
| Lilly USA, LLCForteo | $87 | $666,831172 claims |
| AmgenEnbrel, Otezla | $571 | $653,54287 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $204 | $365,68257 claims |
| Johnson & JohnsonSimponi | $32 | $149,99925 claims |
| UCB, Inc.Cimzia (2 Pack) | $30 | $75,31413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 44 rheumatology providers in Mississippi.
Other rheumatology in Tupelo
- Kirk EddlemanOxford$576K
- Jason TaylorMadison$173K
- Vikas MajithiaJackson$123K
- David WeissHattiesburg$118K
- Matthew CarrollKeesler Afb$56K
- Neal ShparagoJackson$39K
- Seth ComptonMadison$22K
- Sharon HongFlowood$22K
- Nicole WaltonOcean Springs$19K
- Muhammad IjazHattiesburg$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.